Growth Differentiation Factor-15 and the Effect of Dapagliflozin in Heart Failure: Insights From the DAPA-HF Trial
Abstract
BACKGROUND: Growth differentiation factor (GDF)-15, a stress-induced cytokine implicated in systemic energy homeostasis, is associated with adverse outcomes in heart failure (HF). This study evaluated the associations between baseline GDF-15 and the clinical characteristics and outcomes in patients with HF with reduced ejection fraction in the DAPA-HF (Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure) trial. The effect of the sodium-glucose cotransporter-2 inhibitor dapagliflozin on circulating GDF-15 levels and the effect of dapagliflozin on clinical outcomes in relation to baseline GDF-15 concentrations were also examined.
METHODS AND RESULTS: DAPA-HF was a randomized trial of dapagliflozin in patients with HF and LVEF ≤ 40%. GDF-15 was measured at baseline and 12 months. The primary outcome was the composite of worsening HF or cardiovascular death. The median baseline GDF-15 level was 1888 (IQR: 1323-2755) pg/mL. Higher GDF-15 levels were associated with older age, lower body mass index, and greater HF symptom burden. There was a stepwise increase in adjusted risk for the primary outcome across quartiles of baseline GDF-15 (adjusted hazard ratio [Q4 vs Q1] 2.30, 95% CI 1.66-18; P trend < 0.001). Dapagliflozin did not significantly change GDF-15 concentrations over 12 months, compared to placebo (placebo-corrected relative change +4%; 95% CI, -2% to +10%). The relative effect of dapagliflozin on the primary outcome was consistent across GDF-15 quartiles (P…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Chaos and quantum thermalization
- The Dalton quantum chemistry program system
- Cord Blood Leptin and Adiponectin as Predictors of Adiposity in Children at 3 Years of Age: A Prospective Cohort Study
- Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes
- Stable adiabatic quantum batteries
- A novel self-lipid antigen targets human T cells against CD1c(+) leukemias
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.